Phase 4 Atrial Fibrillation Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older who are on long-term dialysis because their kidneys have failed
- People who have a type of irregular heartbeat called atrial fibrillation (either occasional, ongoing, or permanent), confirmed by a heart tracing (ECG) or a monitoring device recording an episode of a certain length
- People who are able to understand what the study involves, including the possible risks and benefits, and can give written consent to participate
Who may not be able to join:
- People whose score on a standard stroke-risk calculator called CHA2DS2-VASc is 1 or lower
- People who need blood-thinning medication for another reason, such as a blood clot in the lungs within the last 6 months, a blood clot in a leg vein within the last 3 months, or having a mechanical heart valve
- People currently taking two different blood-thinning/anti-clotting tablet medications at the same time
- People who have had a cancer diagnosis (other than a common type of non-serious skin cancer) within the last year, are currently being treated for cancer, or have cancer treatment planned
- People who have had a stomach or bowel ulcer found during a camera examination within the last month
- People who have swollen veins in the food pipe (oesophageal varices)
- People with immune system or inherited blood-clotting disorders
- People with certain rare inherited conditions affecting how the body processes a milk sugar called lactose or related sugars (confirm with trial site)
- People who are scheduled to have a spinal tap (needle into the spine)
- People who have abnormal blood vessel formations in the brain
- People who have an artery bulge (aneurysm)
- People with ulcers or wounds of a certain severity level (confirm with trial site)
- People who have had a heart valve infection within the last 3 months
- People who are currently bleeding in a way that makes blood-thinning treatment unsafe
- People who have had urgent or non-routine surgery within the last 7 days
- People who have had a bleed in the brain within the last 4 weeks
- People who have had a low platelet count (a blood cell that helps clotting) within the last 30 days
- People who have had signs of serious liver problems within the last 30 days
- People who are known to be intolerant to the medication warfarin
- People who are currently taking St. John's Wort (a herbal supplement)
- People who have had very high blood pressure readings within the last 30 days
- People who have had an overactive thyroid gland (with a specific hormone level below a set threshold) within the last 30 days
- People who are pregnant or breastfeeding
- People who are already taking part in another clinical trial that could affect the results of this study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Nicholas Carlson, MD PhD, Department of Nephrology, Copenhagen University Hospital Rigshospitalet
Phone: +45 35455927
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Primary efficacy outcome - Number of participants with transient ischemic attack, fatal and non-fatal ischaemic or unspecific stroke; Primary safety outcome - Number of participants with fatal or non-fatal major bleeding
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.